Targetingc-Met by MicroRNAs:the progress for the treatment of hepatocellular carcinoma(HCC) / 医学研究生学报

ABSTRACT

Cancer is one of the world′s deadliest diseases, with low survival rates and increasing incidence in recent years. The successful application of target therapy significantly improved the treatment of tumor. However, primary and/or acquired resistance make tumor treatment facing huge challenges, and novel combinational therapies were required. RNA interference mediated gene inactivation. Alone or combined with other current therapies will be a promising approach to cancer treatment. It improves cure rate and overcomes drug resistance in current treatment options. Hepatocyte Growth Factor/c-Met signaling is one of the most frequently dysregulated pathways inhuman cancers. Abnormal c-Met activation is correlated with poor clinical outcomes and drug resistance in hepatocellular carcinoma (HCC). In recent years, a large number of studies have identified several inhibitors specifically targeting c-Met and microRNAs (miRNAs).This review discusses potential use of c-Met targeting miRNAs, suppressing aberrant c-Met signaling in HCC treatment.